Summary AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that carries out the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development includes MS1819, an autologous yeast recombinant lipase for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with chronic pancreatitis (CP) and cystic fibrosis (CF); AZX1101, a recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections. It works in partnership with other pharmaceutical companies for the development of proteomics and non-systemic therapeutic biologics. The company has operational presence in the France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US. AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers... Research Beam Model: Research Beam Product ID: 2619821 250 USD New
AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile
 
 

AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

  • Category : Pharmaceuticals
  • Published On : October   2017
  • Pages : 27
  • Publisher : GlobalData
 
 
 
Summary

AzurRx BioPharma Inc (AzurRx BioPharma) is a development stage biopharmaceutical company that carries out the research and development of non-systemic biologics for the treatment of patients with gastrointestinal disorders. The company’s products under development includes MS1819, an autologous yeast recombinant lipase for the treatment of exocrine pancreatic insufficiency exocrine (EPI) in patients with chronic pancreatitis (CP) and cystic fibrosis (CF); AZX1101, a recombinant beta lactamases enzyme for the prevention of nosocomial (hospital-acquired) infections. It works in partnership with other pharmaceutical companies for the development of proteomics and non-systemic therapeutic biologics. The company has operational presence in the France and the US. AzurRx BioPharma is headquartered in Brooklyn, New York, the US.

AzurRx BioPharma Inc (AZRX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile provides you comprehensive data and trend analysis of the company's Mergers and Acquisitions (M&As), partnerships and financings. The report provides detailed information on Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnership transactions recorded by the company over a five year period. The report offers detailed comparative data on the number of deals and their value categorized into deal types, sub-sector and regions.

GlobalData derived the data presented in this report from proprietary in-house Pharma eTrack deals database, and primary and secondary research.

Scope

- Financial Deals - Analysis of the company's financial deals including Mergers and Acquisitions, Equity/Debt Offerings, Private Equity, Venture Financing and Partnerships.
- Deals by Year - Chart and table displaying information encompassing the number of deals and value reported by the company by year, for a five year period.
- Deals by Type - Chart and table depicting information including the number of deals and value reported by the company by type such as Mergers and Acquisitions, Equity/Debt Offering etc.
- Deals by Region - Chart and table presenting information on the number of deals and value reported by the company by region, which includes North America, Europe, Asia Pacific, the Middle East and Africa and South and Central America.
- Deals by Sub-sector - Chart and table showing information on the number of deals and value reported by the company, by sub-sector.
- Major Deals - Information on the company's major financial deals. Each such deal has a brief summary, deal type, deal rationale; and deal financials and target Company’s (major public companies) key financial metrics and ratios.
- Business Description - A brief description of the company's operations.
- Key Employees - A list of the key executives of the company.
- Important Locations and Subsidiaries - A list and contact details of key centers of operation and subsidiaries of the company.
- Key Competitors - A list of the key competitors of the company.
- Key Recent Developments - A brief on recent news about the company.

Reasons to Buy

Get detailed information on the company's financial deals that enable you to understand the company's expansion/divestiture and fund requirements
- The profile enables you to analyze the company's financial deals by region, by year, by business segments and by type, for a five year period.

Understand the company's business segments' expansion / divestiture strategy
- The profile presents deals from the company's core business segments' perspective to help you understand its corporate strategy.

Access elaborate information on the company's recent financial deals that enable you to understand the key deals which have shaped the company
- Detailed information on major recent deals includes a summary of each deal, deal type, deal rationale, deal financials and Target Company's key financial metrics and ratios.

Equip yourself with detailed information about the company’s operations to identify potential customers and suppliers.
- The profile analyzes the company's business structure, locations and subsidiaries, key executives and key competitors.

Stay up-to-date on the major developments affecting the company
- Recent developments concerning the company presented in the profile help you track important events.

Gain key insights into the company for academic or business research
- Key elements such as break up of deals into categories and information on detailed major deals are incorporated into the profile to assist your academic or business research needs.

Note*: Some sections may be missing if data is unavailable for the company.
Table of Contents
Table of Contents 3
List of Tables 4
List of Figures 4
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deal Details 10
Venture Financing 10
AzurRx BioPharma Raises USD0.64 Million in Financing 10
Licensing Agreements 11
Azurrx Biopharma Enters into Licensing Agreement with Transchem 11
AzurRx BioPharma Enters into Licensing Agreement with TransChem 12
Equity Offering 13
Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 13
AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 14
AzurRx BioPharma Raises USD5 Million in Private Placement of Units 15
AzurRx BioPharma Raises USD5.3 Million in IPO 16
Debt Offering 18
AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 18
AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 19
Acquisition 20
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 20
AzurRx BioPharma Inc - Key Competitors 21
AzurRx BioPharma Inc - Key Employees 22
AzurRx BioPharma Inc - Locations And Subsidiaries 23
Head Office 23
Other Locations & Subsidiaries 23
Recent Developments 24
Corporate Communications 24
Sep 25, 2017: AzurRx Announces Appointment of Maged Shenouda as Chief Financial Officer 24
Mar 08, 2017: AzurRx Announces Addition of Charles J Casamento to the Board of Directors 25
Government and Public Interest 26
Dec 01, 2016: AzurRx CEO Provides Shareholders With a "State of the Union" Communication 26
Appendix 27
Methodology 27
About GlobalData 27
Contact Us 27
Disclaimer 27

List Of Tables
List of Tables
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Key Facts, 2016 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare Deals By Type, 2011 to YTD 2017 6
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AzurRx BioPharma Inc, Deals By Therapy Area, 2011 to YTD 2017 8
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals Summary, 2011 to YTD 2017 9
AzurRx BioPharma Raises USD0.64 Million in Financing 10
Azurrx Biopharma Enters into Licensing Agreement with Transchem 11
AzurRx BioPharma Enters into Licensing Agreement with TransChem 12
Azurrx Biopharma Plans to Raise Funds through Public Offering of Shares 13
AzurRx BioPharma Raises USD0.4 Million in Private Placement of Units 14
AzurRx BioPharma Raises USD5 Million in Private Placement of Units 15
AzurRx BioPharma Raises USD5.3 Million in IPO 16
AzurRx BioPharma to Raise USD1.12 Million in Private Placement of 12% Debenture Due 2017 18
AzurRx BioPharma Raises USD9 Million in Private Placement of Notes 19
AzurRx BioPharma Acquires ProteaBio Europe for USD7 Million 20
AzurRx BioPharma Inc, Key Competitors 21
AzurRx BioPharma Inc, Key Employees 22
AzurRx BioPharma Inc, Subsidiaries 23
List Of Figures
List of Figures
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 2
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Year, 2011 to YTD 2017 5
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals by Type, 2011 to YTD 2017 6
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Region, 2011 to YTD 2017 7
AzurRx BioPharma Inc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2011 to YTD 2017 8
PURCHASE OPTIONS
 
 
 

How can we help you?

Contact us at the Consulting WP office nearest to you or submit a business inquiry online.


  Contact
 

Subscribe to Our Newsletter